Trident Lifeline
- Market cap
- ₹ 487 Cr.
- P/E
- 23.2x
- P/B
- 4.69x
- 52-week range
- 229.95 – 437.9
- ROE
- 23%
- ROCE
- 21%
- Dividend yield
- 0%
- Debt / equity
- 0.73
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE SME
About
Trident Lifeline Limited (TLL) is an India-based medication provider. The Company produces and sells finished doses. Its geographical segment includes India, Ghana, Kenya, Peru, Cameroon, Venezuela, and the Rest of the World. It discovered manufacturing formulations under its own brands alongside a loan license and a contract manufacturing model. It deals in capsules, tablets, liquid ointments, gels, ice gels, mouthwash, paste, solution, suspension, toothpaste, syrup, and cream. The product portfolio of the Company comprises a wide range of drugs like Anti-Bacterial, Anti-Diarrheal, Anti-Fungal, Anti-Malarial, Anti-Diabetic, Dental Cure, Pr, Multivitamin, Multimineral Nyteraceutoton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Anti-Lipidemic Drug, Anti-Parasiticical and Non-steroidal anti-inflammatory drugs (NSAIDS).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Trident Lifeline against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)23.2 against a typical 34: cheaper than most peers (1st = cheapest).75th of 220
- Sales growth+42.8% against a typical +15.6% from a year earlier.36th of 197
- Profit growth+82.4% against a typical +18.9% from a year earlier.38th of 160
- Share price, 3 months+61.9% against a typical −0.5%.8th of 200
- Size₹ 487.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).101st of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 7 | 19 | 13 | 15 | 12 | 34 | 24 | 31 | 26 | 50 | 34 |
| Expenses | 7 | 6 | 17 | 11 | 11 | 8 | 25 | 18 | 24 | 21 | 39 | 25 |
| Operating Profit | 2 | 1 | 2 | 2 | 4 | 4 | 9 | 5 | 7 | 5 | 11 | 9 |
| OPM % | 20.4% | 20.2% | 12.3% | 18.9% | 26.2% | 34.4% | 25.1% | 21.9% | 21.9% | 19.8% | 22% | 25.3% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 5 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 1 | 2 | 1 | 2 |
| Profit before tax | 2 | 1 | 3 | 3 | 4 | 3 | 6 | 4 | 7 | 6 | 11 | 7 |
| Tax % | 24.7% | 21.6% | 46.9% | 38.7% | 28.5% | 26.5% | −0.3% | 29.3% | 23.2% | 22.8% | 36% | 23.3% |
| Net Profit | 1 | 1 | 2 | 2 | 3 | 3 | 6 | 3 | 5 | 5 | 7 | 5 |
| EPS in Rs | 1.22 | 0.94 | 1.77 | 1.99 | 2.69 | 2.43 | 6.15 | 2.66 | 4.27 | 3.6 | 5.64 | 4.22 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 60%
- TTM
- 66%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 47%
- TTM
- 31%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 11%
- TTM
- —
- 10 Years
- —
- 5 Years
- 21%
- 3 Years
- 20%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Trident Lifeline | ₹ 430.00 | ₹ 487 Cr. | 23.2x | 4.7x | 23% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Hardik Jigishkumar Desai
- Executive Chairman of the Board
- Ashish Anandsingh Bafna
- Chief Financial Officer, Additional Executive Director
- Nikita Sharma
- Compliance Officer, Company Secretary
- Shravan Harikrishna Patel
- Managing Director
- Rupaben Chetanbhai Jariwala
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.